Shilajit Benefits: What the Evidence Actually Supports

This is the area with the strongest human clinical evidence. A study published in Andrologia (2010) gave 100 mg of processed shilajit twice daily for 90 days to oligospermic men; of the 28 who completed it, total sperm count rose 61.4%, motility 12.4–17.4%, and testosterone 23.5% against their own baselines. It was open-label with no placebo group, so the effect sizes should be read as promising rather than established. Biswas TK et al., Andrologia 2010.

A separate RCT by Pandit et al. (2016) in healthy male volunteers aged 45–55 found that purified shilajit (250 mg twice daily for 90 days) significantly increased total testosterone, free testosterone, and DHEAS compared with placebo, with no adverse effects reported. Pandit S et al., Andrologia 2016.

The mechanism is not fully established but may involve stimulation of luteinising hormone (LH) and follicle-stimulating hormone (FSH) at the pituitary level, as well as gonadotropin activity in testicular Leydig cells.

No human trial has tested shilajit for energy or fatigue in healthy adults. The study most often cited for this claim was conducted in rats: shilajit at 25–100 mg/kg for 21 days reversed fatigue behaviours and protected brain mitochondria in a forced-swim model of chronic fatigue. Surapaneni DK et al., J Ethnopharmacol 2012.

The human data that does exist is narrower. In a randomised, double-blind, placebo-controlled trial of 63 recreationally active men, those taking 500 mg/day for 8 weeks lost less strength across a fatiguing leg-extension protocol than placebo — but only within the stronger half of the sample, and not at 250 mg/day. They were not stronger overall; they fatigued less. Keller JL et al., J Int Soc Sports Nutr 2019.

The proposed mechanism involves shilajit's effect on mitochondrial CoQ10 and its role in the electron transport chain — essentially making mitochondria more efficient at producing ATP.

The cognitive research on shilajit is mechanistically compelling but human trial data is limited. In laboratory models, fulvic acid has been shown to inhibit tau protein aggregation — a key pathological feature of Alzheimer's disease — and disaggregate pre-formed tau filaments in vitro. Carrasco-Gallardo C et al., Int J Alzheimers Dis 2012.

In animal models, shilajit has shown benefits in spatial memory tasks and reduced amyloid-β plaque formation. No large-scale human RCTs on cognitive outcomes have been published. This remains a promising but unproven area.

No human trial has tested shilajit for iron status or anaemia. This is worth stating plainly, because a clinical study in women with iron deficiency anaemia is widely cited across the web — including, until we corrected it, on this page. We could not find such a study in PubMed or Europe PMC, and the citation that usually accompanies the claim points to unrelated research.

What is established is compositional. Shilajit contains iron, and its metals are not present as free ions: a 2026 ICP-MS analysis of twelve samples found most metals bound in low-molecular-weight complexes consistent with humic acid. Kamgar E et al., J Trace Elem Med Biol 2026 Fulvic acid is a known metal chelator, and the reasoning is that chelated non-haem iron held in its ferrous (Fe²⁺) form is more readily absorbed than ferric (Fe³⁺) iron. That is a credible mechanism and the reason the claim persists — but a mechanism is not an outcome, and nobody has measured whether it raises haemoglobin in a person. What has actually been trialled is a short list, and iron is not on it.

Some users report improved sleep quality with shilajit supplementation. The biological rationale involves shilajit's effect on GABA receptor activity — an inhibitory neurotransmitter pathway involved in sleep onset — and its adaptogenic properties, which may reduce cortisol-mediated arousal. However, controlled human trials specifically examining sleep outcomes are not yet available. The evidence here is largely anecdotal and mechanistic rather than empirical.

Traditional use of shilajit at altitude dates back thousands of years in Himalayan and Tibetan medicine. A narrative review in the International Journal of Ayurveda Research proposes it as a supplement for people ascending to high altitude, describing it as helping with tiredness, lethargy and chronic fatigue and as stimulating the immune system. The review presents no original data and does not attribute the effect to erythropoiesis, though that mechanism is widely asserted elsewhere without a source. Meena H et al., Int J Ayurveda Res 2010. Controlled human trials at altitude are limited.

Shilajit is widely marketed as anti-inflammatory, and the laboratory work usually cited for it does not say what the marketing says. The best-characterised study fractionated commercial shilajit and found every fraction showed dose-dependent complement-fixing activity in vitro, correlating with carboxylic group content. Schepetkin IA et al., Phytother Res 2009. Complement fixation is an immune-activating property, not a cytokine-suppressing one, and the paper makes no measurement of TNF-α, IL-1β or IL-6. Claims that shilajit inhibits those cytokines are common online but we could not trace them to a study of shilajit. Human trials measuring inflammatory markers as primary outcomes are lacking.